Science
Health Canada flags possible weight-loss risk for under-6s on ADHD stimulants
Safety review of amphetamine and methylphenidate products will push monograph warnings for off-label preschool use; drugs remain authorized from age six.
Published: October 3, 2026 · Updated: October 3, 2026 · 1 min read
Health Canada says children under six who take central nervous system stimulants for ADHD off-label may face a greater risk of weight loss than older children on the same dose, and it will work with manufacturers to update Canadian product monographs accordingly.
The finding is set out in a Summary Safety Review on the Drug and Health Products Portal covering amphetamine-, dextroamphetamine-, lisdexamfetamine-, mixed-salts amphetamine- and methylphenidate-containing ADHD medicines — brands that include Adderall XR, Biphentin, Concerta, Dexedrine, Dyanavel XR, Foquest, Jornay PM, Quillivant ER and Vyvanse, plus generics. In Canada these drugs are authorized for ages six and up; preschool use is off-label even though some jurisdictions abroad authorize certain amphetamine products from age three. Weight loss is already labelled for approved age groups. After a U.S. FDA communication and label updates on extended-release stimulants in younger children, Health Canada reviewed foreign regulatory information, Canada Vigilance reports and scientific literature.
Fourteen cases of weight loss in under-sixes (12 Canadian, two international) were identified but did not individually meet criteria to confirm a causal link. Taken with published studies and foreign-agency data, however, the review concluded there is a possible increased risk versus older children at the same dose. Health Canada is not telling families to stop treatment on their own; it is adding the warning so clinicians can weigh growth monitoring when prescribing off-label. Consumers and professionals are encouraged to report suspected side effects through the Canada Vigilance Program. Coverage in Canadian Healthcare Network and Canada News Media places the review alongside Health Canada’s September Health Product InfoWatch bulletin.
This article is for information only and is not medical advice. Talk to a qualified clinician before starting, stopping or changing any medication.
Sources: Health Canada — Summary Safety Review, CNS stimulants and weight loss under age 6; Canadian Healthcare Network; Canada News Media.
Sources
- Health Canada · other
- Canadian Healthcare Network · other
- Canada News Media · other
Newsletter
News. Context. What matters.
One essential briefing, written for people who would rather understand the story than scroll it.
Unsubscribe anytime. We don’t sell addresses.
Recommended
Science
From the space station, Joshua Kutryk describes the northern lights and relearning daily life as Canadian health studies get under way
In his first news conference from orbit, the Canadian Space Agency astronaut said he has lost five pounds and is taking part in Canadian-led research on astronaut health; a SpaceX cargo ship launched Tuesday with more experiments.
Science
About one in six Canadian doctors reports a disability at least some of the time, CMAJ census study finds
An Ottawa Hospital-led analysis of 2021 long-form census data found mental health and vision were the most commonly reported disabilities, and its authors call for more accessible medical workplaces.
Science
More than half of species assessed at risk since 2017 are overdue for federal listing decisions, SFU-led study finds
Only 17 of 288 COSEWIC-assessed species reached Cabinet on time; none of the marine mammals or marine fish assessed in the period had been forwarded by January 2025, researchers report in FACETS.